The antiinflammatory activity of IgG: the intravenous IgG paradox

How high doses of intravenous IgG (IVIG) suppress autoimmune diseases remains unresolved. We have recently shown that the antiinflammatory activity of IVIG can be attributed to a minor species of IgGs that is modified with terminal sialic acids on their Fc-linked glycans. Here we propose that these...

Descripción completa

Detalles Bibliográficos
Autores principales: Nimmerjahn, Falk, Ravetch, Jeffrey V.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2007
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118416/
https://www.ncbi.nlm.nih.gov/pubmed/17227911
http://dx.doi.org/10.1084/jem.20061788
_version_ 1782141020969893888
author Nimmerjahn, Falk
Ravetch, Jeffrey V.
author_facet Nimmerjahn, Falk
Ravetch, Jeffrey V.
author_sort Nimmerjahn, Falk
collection PubMed
description How high doses of intravenous IgG (IVIG) suppress autoimmune diseases remains unresolved. We have recently shown that the antiinflammatory activity of IVIG can be attributed to a minor species of IgGs that is modified with terminal sialic acids on their Fc-linked glycans. Here we propose that these Fc-sialylated IgGs engage a unique receptor on macrophages that, in turn, leads to the upregulation of an inhibitory Fcγ receptor (FcγR), thereby protecting against autoantibody-mediated pathology.
format Text
id pubmed-2118416
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21184162007-12-13 The antiinflammatory activity of IgG: the intravenous IgG paradox Nimmerjahn, Falk Ravetch, Jeffrey V. J Exp Med Commentaries How high doses of intravenous IgG (IVIG) suppress autoimmune diseases remains unresolved. We have recently shown that the antiinflammatory activity of IVIG can be attributed to a minor species of IgGs that is modified with terminal sialic acids on their Fc-linked glycans. Here we propose that these Fc-sialylated IgGs engage a unique receptor on macrophages that, in turn, leads to the upregulation of an inhibitory Fcγ receptor (FcγR), thereby protecting against autoantibody-mediated pathology. The Rockefeller University Press 2007-01-22 /pmc/articles/PMC2118416/ /pubmed/17227911 http://dx.doi.org/10.1084/jem.20061788 Text en Copyright © 2007, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentaries
Nimmerjahn, Falk
Ravetch, Jeffrey V.
The antiinflammatory activity of IgG: the intravenous IgG paradox
title The antiinflammatory activity of IgG: the intravenous IgG paradox
title_full The antiinflammatory activity of IgG: the intravenous IgG paradox
title_fullStr The antiinflammatory activity of IgG: the intravenous IgG paradox
title_full_unstemmed The antiinflammatory activity of IgG: the intravenous IgG paradox
title_short The antiinflammatory activity of IgG: the intravenous IgG paradox
title_sort antiinflammatory activity of igg: the intravenous igg paradox
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118416/
https://www.ncbi.nlm.nih.gov/pubmed/17227911
http://dx.doi.org/10.1084/jem.20061788
work_keys_str_mv AT nimmerjahnfalk theantiinflammatoryactivityofiggtheintravenousiggparadox
AT ravetchjeffreyv theantiinflammatoryactivityofiggtheintravenousiggparadox
AT nimmerjahnfalk antiinflammatoryactivityofiggtheintravenousiggparadox
AT ravetchjeffreyv antiinflammatoryactivityofiggtheintravenousiggparadox

Ejemplares similares